<DOC>
	<DOCNO>NCT02993198</DOCNO>
	<brief_summary>The Cardio-Oncology program Northwestern offer care cancer patient develop cardiac toxicity chemotherapy . Breast cancer patient tumor marker HER2 necessitate treatment anthracycline and/or trastuzumab pertuzumab-based chemotherapy , know cause cardiac toxicity . Breast cancer patient undergo `` cardio-oncology echocardiogram '' incorporates advance left ventricular assessment utilize deformation strain image chemotherapy treatment surveillance cardiac toxicity . The aim project : 1 . To create registry clinical , echocardiographic variable , biomarkers , genetic analysis use develop risk model predict LV dysfunction early stage breast cancer patient undergo chemotherapy anthracycline and/or trastuzumab pertuzumab-based chemotherapy regimen . 2 . To propose new management algorithm initiation prophylactic beta-blocker therapy early stage breast cancer patient preclinical cardiac toxicity demonstrate strain parameter . 3 . To determine initiation prophylactic beta-blocker therapy patient early cardiac toxicity delay prevent drop LV EF development clinical heart failure . 4 . To explore serial measurement suite novel biomarkers ongoing anticancer treatment presume yet prove predictive cardiac dysfunction woman breast cancer . 5 . To identify DNA biomarkers predilection cardiotoxicity . 6 . To generate hiPSC validate marker predictive cardiotoxicity .</brief_summary>
	<brief_title>A Prospective Study Breast Cancer Patients With Abnormal Strain Imaging</brief_title>
	<detailed_description>150 patient prospectively consented/screened . Over course study , 30 patient expect develop abnormal strain normal EF &gt; 53 % . They randomize 1:1 fashion open label carvedilol vs. treatment . All consent patient receive baseline echocardiogram blood draw biomarkers genetic testing . Patients follow echocardiograms 3 month interval 12 month , completion trastuzumab/pertuzumab therapy . Based echocardiogram finding , patient fall four study arm ( A , B , C , D ) . Patients Arm A ( normal EF normal strain ) Arm D ( decrease EF &gt; 10 % , value &lt; 53 % ) receive current standard care treatment follow registry arm . Arms B C comprise 30 patient normal EF develop preclinical cardiac dysfunction , define change global longitudinal strain &gt; 15 % baseline strain ) &lt; -15 % absolute longitudinal strain prospectively assign 1:1 receive prophylactic carvedilol ( Arm B ) vs. treatment ( Arm C ) . Prophylactic carvedilol initiate start dose 3.125 mg PO BID titrate base blood pressure heart rate . Patients see every 3 week titration phase chemotherapy appointment . At visit , vitals symptom assess dizziness side-effects carvedilol . If patient complains dizziness HR &lt; 50 bpm , SBP &lt; 100 mmHg , dose titration stop dose reduce dose last increased increment . If &gt; 10 % decrease EF value &lt; 53 % next echocardiogram , standard heart failure therapy initiate ( beta-blocker and/or ace-inhibitors ) chemotherapy hold per standard care . If patient require standard care treatment heart failure , diuretic therapy aldosterone antagonist , also initiate . At point , patient consider meet study endpoint . However , improvement change strain EF , patient continue cardiac surveillance echo 3 month interval . Patients assign receive prophylactic carvedilol continue treatment duration chemotherapy 1 year . Prophylactic carvedilol stop completion study . A biomarker substudy conduct 100 patient . These patient labs draw every ten time point , baseline every 6 week 12 month , 1 year post-chemotherapy . A separate blood draw generation hiPSC DNA test would do 100 patient . The blood collection coincide patient 's chemotherapy infusion trastuzumab . These biomarkers allow characterization patient risk develop CTRCD . A `` cardio-oncology '' echocardiogram include standard 2D M-mode Doppler echocardiography , 2D strain imaging , 3D LV volume . This data process on-line off-line within 24 hour completion echocardiogram determine randomization .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cardiovascular Abnormalities</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>1 . Patients &gt; 18 year age HER2overexpressing early stage breast cancer ( Stages I III ) 2 . Pathology report must include HER2 expression , estrogen progesterone receptor status 3 . Normal LV function ( EF &gt; 53 % ) baseline echocardiogram 4 . NYHA functional class III ( symptom , dyspnea 2 block ) 5 . Scheduled receive treatment anthracycline and/or trastuzumab pertuzumabbased regimen 6 . Patients history HTN , hyperlipidemia , diabetes , mild CAD , mild valvular disease permit 7 . Patients concomitant cardiac medication betablockers ( BB ) aceinhibitors ( ACE ) therapy permit . Other noncardiac medication prohibit . 8 . Women childbearing potential sexually active men woman use effective contraception . 9 . Patients must sign informed consent prior registration 1 . LV dysfunction ( EF &lt; 53 % ) 2 . New York Heart Association ( NYHA ) functional class IIIIV ( heart failure symptom less 2 block advance symptom rest ) a. NYHA Classification : I No limitation activity II Slight limitation ordinary activity , symptom rest III Marked limitation less ordinary activity , symptom rest IV Inability carry activity without symptom , symptom rest 3 . Preexisting cardiac disease ( moderatesevere coronary artery disease , moderatesevere valvular heart disease , constrictive/restrictive cardiomyopathy ) 4 . Metastatic breast cancer 5 . Patients ever take BB/ACE therapy exclude . 6 . 2nd 3rd degree AV block 7 . Sick sinus syndrome 8 . Patients severe bradycardia ( &lt; 50 bpm ) severe hypotension ( SBP &lt; 85 mmHg ) 9 . Severe liver dysfunction define ChildTurcottePugh class B &amp; C ( significant functional compromise decompensated disease ) 10 . Moderatesevere Asthma 11 . Hypersensitivity betablockers 12 . Patients pregnant/lactating eligible 13 . Unwilling consent/assent blood donation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>